Beijing Luzhu Biotechnology Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Beijing Luzhu Biotechnology's earnings have been declining at an average annual rate of -83.6%, while the Biotechs industry saw earnings growing at 31.7% annually.
Belangrijke informatie
-83.6%
Groei van de winst
-75.9%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 11.0% |
| Inkomstengroei | n/a |
| Rendement op eigen vermogen | -29.6% |
| Nettomarge | n/a |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Beijing Luzhu Biotechnology geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -280 | 91 | 220 |
| 31 Mar 24 | 0 | -265 | 89 | 196 |
| 31 Dec 23 | 0 | -249 | 87 | 173 |
| 30 Sep 23 | 0 | -201 | 85 | 121 |
| 30 Jun 23 | 0 | -152 | 82 | 69 |
| 31 Mar 23 | 0 | -439 | 84 | 80 |
| 31 Dec 22 | 0 | -725 | 86 | 91 |
Kwaliteitswinsten: 2480 is currently unprofitable.
Groeiende winstmarge: 2480 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Insufficient data to determine if 2480's year-on-year earnings growth rate was positive over the past 5 years.
Versnelling van de groei: Unable to compare 2480's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 2480 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Rendement op eigen vermogen
Hoge ROE: 2480 has a negative Return on Equity (-29.65%), as it is currently unprofitable.